Division of Endocrinology, Diabetology, and Clinical Nutrition, University Hospital of Berne Inselspital, Freiburgstrasse 15, CH 3010 Berne, Switzerland.
Endocrinol Metab Clin North Am. 2010 Dec;39(4):791-800. doi: 10.1016/j.ecl.2010.09.003.
Glucagonlike peptide-1 receptors (GLP-1R) play an increasingly important role in endocrine gastrointestinal tumor management. In particular, virtually all benign insulinomas express GLP-1R in high density. Exendin-4 is a GLP-1 analog that has a longer half-life than GLP-1. Targeting GLP-1R by (111)In-DOTA-exendin-4 or (111)In-DPTA-exendin-4 offers a new approach that permits the successful localization of small benign insulinomas. It is likely that this new noninvasive technique has the potential to replace the invasive localization by selective arterial stimulation and venous sampling.
胰高血糖素样肽-1 受体（GLP-1R）在胃肠内分泌肿瘤的治疗中发挥着越来越重要的作用。特别是，几乎所有的良性胰岛素瘤都高度表达 GLP-1R。Exendin-4 是一种 GLP-1 类似物，其半衰期长于 GLP-1。用 (111)In-DOTA-exendin-4 或 (111)In-DPTA-exendin-4 靶向 GLP-1R 为成功定位小的良性胰岛素瘤提供了一种新方法。这种新的非侵入性技术很可能具有取代选择性动脉刺激和静脉取样的侵入性定位的潜力。
